Enliven Therapeutics released new Phase 1 data for its chronic myeloid leukemia program (CML) it hopes can eventually compete with Novartis’ Scemblix.
The experimental therapy …
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
Vancouver, Canada, May 07, 2024 (GLOBE NEWSWIRE) — Clearmind Medicine Inc. (Nasdaq: CMND), (FSE: CWY0) (“Clearmind” or the “Company”), a clinical-stage biotech company focused on discovery and
The joint and individual correlations of CVD/T2D and BMI with cancer risk.
Dive Brief: J&J has limited the use of three models of Megadyne patient return electrodes due to the risk of burns. In a June recall